Answers are grounded in this paper and cite their sources.
To compare the risk of developing kidney outcomes with use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) versus use of sodium-glucose cotransporter-2 (SGLT2) inhibitors among individuals with diabetes.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: